nintedanib pulmonary fibrosis
Selected indexed studies
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (BMC Pulm Med, 2021) [PMID:34895203]
- Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. (Ann Am Thorac Soc, 2022) [PMID:35499854]
- Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice. (Inflammation, 2023) [PMID:37160579]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. (2021) pubmed
- Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. (2015) pubmed
- Nintedanib Ameliorates Bleomycin-Induced Pulmonary Fibrosis, Inflammation, Apoptosis, and Oxidative Stress by Modulating PI3K/Akt/mTOR Pathway in Mice. (2023) pubmed
- Idiopathic pulmonary fibrosis. (2023) pubmed
- Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. (2022) pubmed
- Nintedanib for Idiopathic Pulmonary Fibrosis. (2019) pubmed
- Idiopathic Pulmonary Fibrosis. (2018) pubmed
- Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. (2024) pubmed
- Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. (2024) pubmed
- Nintedanib Mitigates Radiation-Induced Pulmonary Fibrosis by Suppressing Epithelial Cell Inflammatory Response and Inhibiting Fibroblast-to-Myofibroblast Transition. (2024) pubmed